Leukemia Stem Cells:
Targeting Acute Myeloid Leukemia's Achilles Heel
Brian Jonas, M.D., Ph.D.
UC Davis School of Medicine
Tuesday, April 21th
6:00 - 7:00 pm
University Union, Ballroom
The Sacramento State Topics in Regenerative Medicine Lecture Series welcomes Dr. Brian Jonas, Assistant Professor at the UC Davis School of Medicine. His talk, titled "Leukemia Stem Cells: Targeting Acute Myeloid Leukemia's Achilles Heel," will focus on the efforts being taken to combat AML and other bone marrow cancers.
Acute myeloid leukemia (AML) is a heterogeneous group of aggressive clonal bone marrow cancers characterized by the expansion of functionally impaired immature myeloid cells. In 2015, an estimated 20,830 new cases of AML will be diagnosed in the United States with an estimated 12,730 deaths. AML is clinically characterized by signs and symptoms of bone marrow failure, and it is rapidly fatal if left untreated. AML, and other bone marrow cancers, such as acute lymphoblastic leukemia and myelodysplastic syndrome (MDS), are propagated and maintained by chemoresistant and quiescent leukemia stem cells (LSC). Targeted elimination of LSC represents an attractive therapeutic approach to improve outcomes and cure patients with these lethal diseases.
Dr. Jonas received his M.D. and Ph.D. degrees from UC Davis in 2007, and he completed his residency, clinical fellowship and post-doctoral fellowship at Stanford in 2013. He joined the faculty at UC Davis late 2013 and is developing a clinical and translational research program focusing on the acute leukemias and MDS. He is an NIH/NCI K12 scholar in the UC Davis Paul Calabresi Clinical Oncology K12 Program and is co-investigator on a newly awarded NIH/NCI R01 grant to develop a novel LSC-targeting nanoparticle.
|Regenerative Medicine Lecture Series
Dr. Rosalee Carter
Office phone: (916) 278-7391
STEM Scholars Series
Coordinator, Center for STEM Excellence